Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 11Terminated 3Unknown 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Docetaxel 2sargramostim 1Prednisone 1Mycobacterium w vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Hormone Refractory Prostate Cancer × Clear all
NCT00313482 2012-05-11

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Veeda Oncology

Phase 2 Terminated
35 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00906243 2012-04-04

RNActive®-Derived Therapeutic Vaccine

University of Florida

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡